Loading...
Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both earl...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3575209/ https://ncbi.nlm.nih.gov/pubmed/23430730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S27733 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|